BIONOMICS LIMITEDFI
For the period ended Jun 30, 2024. Filed Sep 30, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Sep 30, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Date: September 30, 2024 | BIONOMICS | |
|---|---|---|
| By: | /s/ Spyridon Papapetropoulos | |
| Spyridon Papapetropoulos | ||
| Chief Executive Officer and Director | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Name | Position | Date |
|---|---|---|
| /s/ Spyridon Papapetropoulos | Chief Executive Officer and Director | September 30, 2024 |
| Spyridon Papapetropoulos | (principal executive officer) | |
| /s/ Tim Cunningham | Chief Financial Officer | September 30, 2024 |
| Tim Cunningham | (principal financial officer) | |
| /s/ Adrian Hinton | Financial Controller | September 30, 2024 |
| Adrian Hinton | (principal accounting officer) | |
| /s/ Miles Davies | Director | September 30, 2024 |
| Miles Davies | ||
| /s/ Alan Fisher | Director | September 30, 2024 |
| Alan Fisher | ||
| /s/ Jane Ryan | Director | September 30, 2024 |
| Jane Ryan, Ph.D. | ||
| /s/ Aaron Weaver | Director | September 30, 2024 |
| Aaron Weaver | ||
| /s/ David Wilson | Director | September 30, 2024 |
| David Wilson | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.